Orthofix International (OFIX) vs. Antares Pharma (NASDAQ:ATRS) Critical Contrast

Orthofix International (NASDAQ: OFIX) and Antares Pharma (NASDAQ:ATRS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk and institutional ownership.

Profitability

This table compares Orthofix International and Antares Pharma’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Orthofix International 0.33% 10.26% 7.57%
Antares Pharma -32.06% -43.05% -24.14%

Risk and Volatility

Orthofix International has a beta of 0.22, indicating that its share price is 78% less volatile than the S&P 500. Comparatively, Antares Pharma has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.

Valuation & Earnings

This table compares Orthofix International and Antares Pharma’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Orthofix International $409.79 million 2.40 $3.05 million $0.07 770.54
Antares Pharma $52.22 million 7.17 -$24.33 million ($0.11) -21.73

Orthofix International has higher revenue and earnings than Antares Pharma. Antares Pharma is trading at a lower price-to-earnings ratio than Orthofix International, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

95.8% of Orthofix International shares are held by institutional investors. Comparatively, 34.7% of Antares Pharma shares are held by institutional investors. 5.6% of Orthofix International shares are held by insiders. Comparatively, 11.6% of Antares Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for Orthofix International and Antares Pharma, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Orthofix International 0 0 5 0 3.00
Antares Pharma 0 0 3 1 3.25

Orthofix International presently has a consensus target price of $53.30, indicating a potential downside of 1.17%. Antares Pharma has a consensus target price of $4.08, indicating a potential upside of 70.50%. Given Antares Pharma’s stronger consensus rating and higher possible upside, analysts clearly believe Antares Pharma is more favorable than Orthofix International.

Summary

Orthofix International beats Antares Pharma on 9 of the 15 factors compared between the two stocks.

Orthofix International Company Profile

Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim. The Biologics products include AlloQuent Structural Allografts, Trinity ELITE, Trinity Evolution and VersaShield. The Extremity Fixation products include Fixator, Eight-Plate Guided Growth System and Contours VPS Volar Plating System III. The Spine Fixation products include Hallmark Anterior Cervical Plate System, Ascent LE Posterior Occipital Cervico-Thoracic (POCT) System, Firebird Deformity Correction System, Phoenix Minimally Invasive Spinal Fixation System, Samba-Screw System, LONESTAR Cervical Stand Alone (CSA), SKYHAWK Lateral Interbody Fusion System & Lateral Plate System and CENTURION POCT System.

Antares Pharma Company Profile

Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. The Company’s subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors. The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies. The Company has developed OTREXUP (methotrexate) injection, which is a single dose, disposable auto injector.

Receive News & Ratings for Orthofix International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply